Remdesivir (GS-5734)

Remdesivir, also known as GS-5734, is an antiviral drug, and a novel nucleotide analog prodrug. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74nM in HAE cells after treatment for 24h. GS-5734 inhibits both epidemic and zoonotic coronaviruses. It was developed by Gilead Sciences as a treatment for filovirus infections such as Ebola virus disease and Marburg virus. Remdesivir share the same core structure with that of GS-441524. Remdesivir may consider as a prodrug of GS-441524.

Remdesivir has been found to show reasonable antiviral activity against more distantly related viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus, and MERS-coronavirus. GS-5734 was rapidly pushed through clinical trials due to the 2013–2016 West African Ebola virus epidemic crisis, eventually being used in at least one human patient despite its early development stage at the time. Preliminary results have been promising, and further clinical trials are planned.

2-Ethylbutyl (2S)-2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate; 2-ethylbutyl ((((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate; GS-5734; Prodrug of GS-441524

1809249-37-3

602.58

C27H35N6O8P

White to off-white solid

≥98%

C, 53.82; H, 5.85; N, 13.95; O, 21.24; P, 5.14

Soluble in DMSO

Store at -20°C under inert atmosphere. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. Toxicity and Hazards